The Impact of Weight on IGF-1 Levels in Short-Statured Children Treated With Growth Hormone.

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice Pub Date : 2025-10-22 DOI:10.1016/j.eprac.2025.10.007

Keren Smuel Zilberberg, Michal Yackobovitch-Gavan, Ariel Tenenbaum, Liron Tirosh Legmann, Liora Lazar, Moshe Phillip, Tal Oron

{"title":"The Impact of Weight on IGF-1 Levels in Short-Statured Children Treated With Growth Hormone.","authors":"Keren Smuel Zilberberg, Michal Yackobovitch-Gavan, Ariel Tenenbaum, Liron Tirosh Legmann, Liora Lazar, Moshe Phillip, Tal Oron","doi":"10.1016/j.eprac.2025.10.007","DOIUrl":null,"url":null,"abstract":"Objective: To examine how weight status influences insulin-like growth factor-1 (IGF-1) levels and growth outcomes in short statured children treated with GH for growth hormone deficiency (GHD) or idiopathic short stature (ISS).Methods: This retrospective cohort study analysed 293 children (95 GHD, 197 ISS) treated with GH in an endocrine clinic at a tertiary pediatric referral centre (2016-2021). Data were collected at baseline and years 1-3, including auxological parameters, pubertal staging, GH dose, and IGF-1 levels. Mixed-model analyses examined the effects of weight on height standard deviation score (Ht-SDS), IGF-1-SDS, and GH dosing over a three-year period.Results: BMI-SDS positively correlated with IGF-1-SDS (B=0.150, p<0.001). Overweight/obese children consistently demonstrated higher IGF-1 SD scores than normal-weight children (p < 0.001), despite receiving lower GH doses (p = 0.034). Both weight groups showed comparable Ht-SDS improvements over time (p<0.001), with no significant difference in growth response (p=0.685). Body surface area was positively associated with IGF-1-SDS at all time points. Pubertal status significantly influenced IGF-1 levels.Conclusions: Weight status has a significant influence on IGF-1 levels in children treated with GH, with overweight/obese children exhibiting elevated IGF-1 levels despite receiving lower GH doses. These elevations likely represent a normal physiological response rather than overtreatment. Our findings underscore the importance of considering weight when monitoring IGF-1 levels and adjusting GH doses in clinical practice.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eprac.2025.10.007","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To examine how weight status influences insulin-like growth factor-1 (IGF-1) levels and growth outcomes in short statured children treated with GH for growth hormone deficiency (GHD) or idiopathic short stature (ISS).

Methods: This retrospective cohort study analysed 293 children (95 GHD, 197 ISS) treated with GH in an endocrine clinic at a tertiary pediatric referral centre (2016-2021). Data were collected at baseline and years 1-3, including auxological parameters, pubertal staging, GH dose, and IGF-1 levels. Mixed-model analyses examined the effects of weight on height standard deviation score (Ht-SDS), IGF-1-SDS, and GH dosing over a three-year period.

Results: BMI-SDS positively correlated with IGF-1-SDS (B=0.150, p<0.001). Overweight/obese children consistently demonstrated higher IGF-1 SD scores than normal-weight children (p < 0.001), despite receiving lower GH doses (p = 0.034). Both weight groups showed comparable Ht-SDS improvements over time (p<0.001), with no significant difference in growth response (p=0.685). Body surface area was positively associated with IGF-1-SDS at all time points. Pubertal status significantly influenced IGF-1 levels.

Conclusions: Weight status has a significant influence on IGF-1 levels in children treated with GH, with overweight/obese children exhibiting elevated IGF-1 levels despite receiving lower GH doses. These elevations likely represent a normal physiological response rather than overtreatment. Our findings underscore the importance of considering weight when monitoring IGF-1 levels and adjusting GH doses in clinical practice.

查看原文本刊更多论文

体重对矮小儿童接受生长激素治疗后IGF-1水平的影响

目的：研究体重状况对矮小儿童因生长激素缺乏症（GHD）或特发性矮小（ISS）接受生长激素治疗时胰岛素样生长因子-1 （IGF-1）水平和生长结局的影响。方法：这项回顾性队列研究分析了293名儿童（95名GHD， 197名ISS）在三级儿科转诊中心的内分泌诊所接受GH治疗（2016-2021）。在基线和1-3年收集数据，包括生理参数、青春期分期、生长激素剂量和IGF-1水平。混合模型分析检查了体重对身高标准偏差评分（Ht-SDS）、IGF-1-SDS和生长激素剂量在三年期间的影响。结果：BMI-SDS与IGF-1- sds呈正相关（B=0.150）。结论：体重状况对接受生长激素治疗的儿童的IGF-1水平有显著影响，超重/肥胖儿童尽管接受较低的生长激素剂量，但IGF-1水平升高。这些升高可能代表正常的生理反应，而不是过度治疗。我们的发现强调了在临床实践中监测IGF-1水平和调整生长激素剂量时考虑体重的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine Practice ENDOCRINOLOGY & METABOLISM-

CiteScore

7.60

自引率

2.40%

发文量

546

审稿时长

41 days

期刊介绍： Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.